Kumquat Biosciences

Kumquat Biosciences is a clinical-stage biotech company based in San Diego, California, founded by pioneers of the KRAS oncology field who previously co-founded Intellikine, Araxes/Wellspring Biosciences, and Kura Oncology. The company brings together drug discovery and clinical experts to translate breakthrough science into best-in-class therapeutics that provide sustainable benefits to cancer patients. Kumquat focuses on novel small-molecule inhibitors targeting the RAS pathway — including multiple KRAS mutant programs — and combines these targeted agents with immuno-oncology approaches to achieve durable anti-tumor responses. The company has entered major strategic collaborations with Bayer (Phase I KRAS G12D inhibitor) and Takeda (oral immuno-oncology candidate), reflecting strong validation of its pipeline by leading global pharma partners.